CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 137 enrolled
Drug / intervention
ALA +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02632110
NCT02632110Phase 2Completed

A Phase 2 Study of the Effect of Microneedle Lesion Preparation, Incubation Time and Light Power Density on Photodynamic Therapy With Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% + Blue Light for the Field Treatment of Actinic Keratoses on the Face

DUSA Pharmaceuticals, Inc.·interventional·Posted Dec 16, 2015·Updated Jan 18, 2018

In Brief

A Phase 2 clinical trial evaluating ALA, Topical Solution Vehicle, and 3 other interventions for Actinic Keratosis. Completed, enrolled 137 participants across 8 sites.

Detailed Summary

The purpose of this study is to determine the viability of microneedle lesion preparation (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis (AK) field on the face.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 16, 2015
Enrollment StartMar 1, 2016
Primary CompletionSep 12, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.5 years ago

Interventions

ALAdrug

20% ALA applied to face prior to light treatment

Topical Solution Vehicledrug

Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face prior to light treatment

IBL 10 mWdevice

10 J/cm2 blue light delivered at 10 mW/cm2 for 16 minutes 40 seconds

Microneedle lesion preparationprocedure

Microneedling of all visible/palpable AK lesions prior to solution application.

IBL 20 mWdevice

10 J/cm2 blue light delivered at 20 mW/cm2 for 8 minutes 20 seconds